A recent 2024 study published in Frontiers in Pharmacology has highlighted a persistent issue in the hemp industry: significant discrepancies between what is on the label and what is inside the bottle. After analyzing 202 CBD products, researchers discovered that 74% of the samples deviated from their advertised potency by more than 10%. Furthermore, 26% of the items failed to meet the basic product classification defined on their packaging. These findings suggest that for many consumers, CBD labels remain an unreliable indicator of actual dosage.
The study examined a diverse range of formats, including 100 tinctures, 48 gummies, 34 vape products, and 20 topicals. The data revealed that potency errors and contamination risks vary significantly depending on the delivery method, creating unique challenges for both manufacturers and consumers.
The Hidden Risks of Impurities and Mislabeling in CBD Products
Purity is as much of a concern as potency. The same 2024 analysis identified heavy metals in 44 products and residual solvents in 181 samples. Additionally, pesticide screenings found 26 different chemical compounds across 30 products, suggesting that many contaminants originate during the cultivation process.
Hemp is a bioaccumulator, meaning it efficiently absorbs metals and residues from the soil. Because of this, the quality of cultivation inputs is the primary factor in determining the purity of the final extract. However, the extraction process itself introduces further risks. If solvent-based extraction is rushed or performed with poorly maintained equipment, trace chemicals can remain in the distillate used to manufacture tinctures and edibles.
Testing finished goods is the only way to ensure safety, as contamination can occur at any point from harvest to bottling. Brands that rely solely on raw biomass testing are essentially verifying the cheapest part of their supply chain while leaving the final consumer product unvalidated.
This lack of precision is not a new phenomenon. Previous research on 84 over-the-counter CBD products found that only 31% were accurately labeled. A National Institutes of Health (NIH) study showed similar results, with 26% of products containing less CBD than promised and 43% containing more. This decade-long measurement problem is why modern regulators view a current Certificate of Analysis (COA) as a mandatory requirement for market entry.
The physical format of a product also influences its consistency. In tinctures, CBD must stay evenly suspended in a carrier oil; if the solution separates during storage, the concentration at the top of the bottle will differ from the bottom. Gummies face “hot spot” issues, where the active ingredient is not distributed evenly through the gelatin or pectin slurry before it sets. When labs test a composite sample of 10 gummies, they often miss the individual variations that a customer will actually experience.
Potency accuracy is a critical safety issue because CBD is a pharmacologically active compound. In an FDA-funded randomized trial, healthy adults taking CBD twice daily for 28 days showed elevated liver enzymes (hepatic aminotransferase) in some cases. Side effects included somnolence, diarrhea, and eosinophilia. While these levels returned to normal once dosing stopped, the results highlight the need for precise dosing.
Furthermore, CBD is known to inhibit certain cytochrome P450 enzymes. These enzymes are responsible for how the liver metabolizes various prescription medications, including anticonvulsants and blood thinners. If a patient unknowingly consumes 40% more CBD than their label indicates, they could face an undetected and potentially dangerous change in how their other medications function.
Regulatory Oversight and the Impact of Product Claims
Since 2019, the FDA has sent more than 200 warning letters to companies in the cannabinoid space. Most recently, in April 2025, the Center for Veterinary Medicine targeted several brands for selling unapproved cannabis products for medical uses. These enforcement actions often focus as much on marketing language as they do on manufacturing standards.
Under the Food, Drug, and Cosmetic Act, making a therapeutic or disease-related claim can legally transform a supplement into an unapproved drug. Once a product is classified this way, it is held to much stricter manufacturing requirements. Companies that avoid making health claims generally stay within a regulatory category that is easier to satisfy with standard quality control systems.
Why Third-Party Testing Matters to Banks and Insurers
Laboratories are not the only ones scrutinizing Certificates of Analysis. Underwriters and payment processors use these documents to gauge a company’s operational integrity. Financial institutions that handle CBD transactions often view organized, transparent lab records as a sign of a low-risk, disciplined business. Clear documentation allows these reviewers to approve accounts without the need for extensive follow-up requests.
Similarly, retailers and insurance providers require proof that a product’s contents match its label before they agree to carry it or provide liability coverage. For these stakeholders, the paperwork generated by a consistent laboratory program is the primary evidence of product safety.
Establishing a Gold-Standard Testing Protocol for Hemp Brands
To meet regulatory and institutional standards, every production lot must have its own COA linked to a specific lot number on the packaging. These tests should be performed by laboratories with ISO 17025 accreditation. Relying on composite testing—where multiple batches are averaged together—is insufficient because it masks the very inconsistencies the test is supposed to find.
A comprehensive testing panel should include:
- Cannabinoid potency
- Residual solvents
- Heavy metals
- Pesticides
- Microbial activity
- Mycotoxins
Maintaining retention samples from every lot is also essential. This allows a brand to re-test a specific batch if a customer complaint arises months later. Transparency is further improved by making these COAs easily accessible to consumers via a lot-number index or QR code.
Supply chain management is the foundation of this process. Buying extracts on the open market often means inheriting unknown cultivation practices. Brands should conduct their own independent tests rather than relying solely on the seller’s paperwork. Additionally, working with qualified suppliers who agree to periodic audits and strict rejection rights helps ensure long-term consistency.
When complaints are logged and matched to specific lot numbers, companies can trace a problem to its source in days. This rapid response is what prevents a minor error from turning into a widespread crisis.
The True Business Expense of Substandard Quality Control
The fallout from a contaminated or mislabeled batch is rarely contained. Product recalls involve not only the destruction of inventory but also the high cost of forensic laboratory work to determine the scope of the problem. However, the most significant damage often happens after the recall. Acquiring banks may freeze accounts, retailers may drop the product line, and insurers may significantly increase premiums for product liability.
The FDA has consistently reminded the public that it does not review the manufacturing processes of unapproved CBD products. The agency warns that the long-term effects of consuming unsafe levels of heavy metals or pesticides remain unknown. This warning is a key component of the risk assessments used by banks and insurers when deciding whether to work with a CBD merchant.
While a full-panel test for a batch may cost several hundred dollars, the cost of a failed batch can be the permanent closure of a business. Investing in rigorous, transparent testing is not just a regulatory necessity; it is a fundamental requirement for business survival.
Final Summary: The CBD industry continues to struggle with potency accuracy and contaminant control, with a majority of products failing to meet label claims. Ensuring consumer safety and business longevity requires a shift from basic biomass testing to rigorous, lot-specific finished-good analysis. By prioritizing ISO-accredited testing and transparent documentation, brands can protect consumers from unintended health risks while satisfying the strict requirements of regulators, banks, and insurers.
